Drug Profile
AZD 6703
Alternative Names: AZD-6703Latest Information Update: 31 Jul 2007
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antirheumatics
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 31 Jul 2007 Discontinued - Phase-I for Rheumatoid arthritis (unspecified route)
- 01 Feb 2007 Phase-I clinical trials in Rheumatoid arthritis (unspecified route)
- 04 Jul 2006 This compound is still in active development